← Leaderboards
Stephen Patrick Hunger
University Of Florida
$7,938,370
Attributed
$16,084,699
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,239,077 · 12
By mechanism
U2C$13,154,378 · 1
T32$5,005,259 · 2
K12$4,618,004 · 1
U01$2,865,146 · 1
RC2$1,708,950 · 1
RC4$1,573,220 · 1
Top collaborators
- Cheryl L Willman7 shared
- Lynn M Schuchter6 shared
- Kai Tan6 shared
- Ivan Maillard5 shared
- Douglas K Graham4 shared
- Mignon Lee-Cheun Loh3 shared
- Charles G. Mullighan3 shared
- Michael J Borowitz2 shared
Most similar at University Of Florida
Same institution · by research overlap
- Weihong Tan$6,516,065
- Scott A. Tibbetts$9,656,998
- Grant McFadden$8,340,507
- Xingming Deng$11,809,682
- Meenakshi Devidas$3,105,019
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsBaseGrantMalignant Childhood NeoplasmSourceResearch PersonnelChemotherapyClinical ResearchDiagnosisMutationTrainingNew Therapeutic TargetCessation Of LifeHigh RiskTraining ProgramsAlgorithmsCancer CenterPediatric HospitalsPhiladelphiaPediatric OncologyAdultNext GenerationPennsylvaniaTranslational Research
Grant awards (39)
Physician Scientist Training in Clinical Oncology$784,822
K12 · FY2025 · CA
Physician Scientist Training in Clinical Oncology$772,275
K12 · FY2024 · CA
Cancer Center Research Training Program$499,533
T32 · FY2024 · CA · contact PI
Center for Pediatric Tumor Cell Atlas - Admin Supplement$924,671
U2C · FY2023 · CA
Physician Scientist Training in Clinical Oncology$767,856
K12 · FY2023 · CA
Cancer Center Research Training Program$470,644
T32 · FY2023 · CA · contact PI
Center for pediatric tumor cell atlas$2,175,874
U2C · FY2022 · CA
Physician Scientist Training in Clinical Oncology$772,048
K12 · FY2022 · CA
Cancer Center Research Training Program$440,762
T32 · FY2022 · CA · contact PI
Center for pediatric tumor cell atlas$2,638,218
U2C · FY2021 · CA
Physician Scientist Training in Clinical Oncology$773,096
K12 · FY2021 · CA
Cancer Center Research Training Program$377,847
T32 · FY2021 · CA · contact PI
Center for pediatric tumor cell atlas$2,261,333
U2C · FY2020 · CA
Physician Scientist Training in Clinical Oncology$747,907
K12 · FY2020 · CA
Cancer Center Research Training Program$468,519
T32 · FY2020 · CA · contact PI
Center for pediatric tumor cell atlas$2,593,508
U2C · FY2019 · CA
Cancer Center Research Training Program$400,682
T32 · FY2019 · CA · contact PI
Center for pediatric tumor cell atlas$2,560,774
U2C · FY2018 · CA
Cancer Center Research Training Program$415,534
T32 · FY2018 · CA · contact PI
MOLECULAR SIGNATURES FOR OUTCOME PREDICTION AND THERAPEUTIC TARGETING IN ALL$575,377
U01 · FY2015 · CA
MOLECULAR SIGNATURES FOR OUTCOME PREDICTION AND THERAPEUTIC TARGETING IN ALL$559,590
U01 · FY2014 · CA
Post Graduate Training in Pediatric Oncology$386,519
T32 · FY2014 · CA
MOLECULAR SIGNATURES FOR OUTCOME PREDICTION AND THERAPEUTIC TARGETING IN ALL$545,046
U01 · FY2013 · CA
Post Graduate Training in Pediatric Oncology$358,852
T32 · FY2013 · CA
MOLECULAR SIGNATURES FOR OUTCOME PREDICTION AND THERAPEUTIC TARGETING IN ALL$585,133
U01 · FY2012 · CA
Post Graduate Training in Pediatric Oncology$374,504
T32 · FY2012 · CA · contact PI
MOLECULAR SIGNATURES FOR OUTCOME PREDICTION AND THERAPEUTIC TARGETING IN ALL$600,000
U01 · FY2011 · CA
Post Graduate Training in Pediatric Oncology$320,906
T32 · FY2011 · CA · contact PI
Identifying the spectrum of genetic alterations in high risk ALL$1,573,220
RC4 · FY2010 · CA
Targeted Therapies for Childhood Acute Lymphoblastic Leukemia$876,194
RC2 · FY2010 · CA · contact PI
Targeted Therapies for Childhood Acute Lymphoblastic Leukemia$832,756
RC2 · FY2009 · CA
Postgraduate Training in Pediatric Oncology$198,863
T32 · FY2009 · CA · contact PI
Postgraduate Training in Pediatric Oncology$292,094
T32 · FY2008 · CA · contact PI
ANBL0032, PHASE III RANDOMIZED STUDY OF CHIMERIC ANTI-GD2 IN HIGH RISK NEUROBLAE$22,512
M01 · FY2007 · RR · contact PI
PHASE I STUDY OF ERBITUX (CETUXIMAB) IN PED SUBJ WITH SOLID TUMORS CA225-085$9,058
M01 · FY2007 · RR · contact PI
A MULTICENTER PHASE I TRIAL OF 17-N-ALLYLAMINO-17-DEMETHOXY GELDANAMYCIN$14,523
M01 · FY2006 · RR · contact PI
Measuring Asparagine Synthetase Expression in Leukemia$130,950
R21 · FY2005 · CA
A MULTICENTER PHASE I TRIAL OF 17-N-ALLYLAMINO-17-DEMETHOXY GELDANAMYCIN (17-AS$6,164
M01 · FY2005 · RR
Measuring Asparagine Synthetase Expression in Leukemia$130,913
R21 · FY2004 · CA